13.40SEK-1.11%Mkt Cap: 94.59M SEKP/E: —Last update: 2026-06-01
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natu…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap94.59M SEK
Enterprise Value78.58M SEK
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-36.89M SEK
Revenue/Share—
Last Price13.40 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees4
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.02
EV/Revenue—
P/S—
P/B3.84
EPS (TTM)-5.59
EPS (Forward)—
52W Range
11.656% of range39.00
52W High39.00 SEK
52W Low11.65 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-147.97%
ROA-122.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.92M SEK
CapEx (TTM)129.00K SEK
FCF Margin—
FCF Yield-25.54%
Net Debt-17.07M SEK
Net Debt/EBITDA0.44
Balance Sheet
Debt/Equity0.00
Current Ratio3.31
Quick Ratio3.20
Book Value/Sh3.532 SEK
Cash/Share2.418 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateMay 28, 2025
Analyst Consensus
Rating—
Target (Mean)75.00 SEK
Target Range75.00 SEK – 75.00 SEK
# Analysts1
Ownership
Shares Out.7.06M
Float3.56M
Insiders70.41%
Institutions3.79%
Technical
SMA 5014.12 (-5.1%)
SMA 20020.00 (-33.0%)
Beta0.30
S&P 52W Chg27.70%
Avg Vol (30d)3.88K
Avg Vol (10d)3.87K
Technical Indicators
RSI (14)41.9
MACD-0.3310
MACD Signal-0.1745
MACD Hist.-0.1565
BB Upper16.21 SEK
BB Middle14.47 SEK
BB Lower12.73 SEK
BB Width24.01%
ATR (14)0.7103 SEK
Vol Ratio (20d)0.28x